Advances and uncertainties in fat embolism syndrome: a review Authors: Takahito Miyake, Hideshi Okada, Norihide Kanda Published: 2026 ABSTRACT SummaryFat embolism syndrome (FES) is a complex and potentially life-threatening condition resulting from fat particles entering the circulation, leading to embolic and inflammatory injury across multiple organs, particularly the lungs, brain, and skin. Although the classical triad of respiratory distress, neurological dysfunction, and petechial rash was first described decades ago, clinical presentation remains heterogeneous and often non-specific, complicating timely diagnosis. Existing criteria (Gurd, Wilson, and Lindeque) lack robust validation and remain inadequate in current practice. Imaging modalities, particularly chest CT and brain MRI, alongside emerging biomarkers, such as interleukin-6, might improve diagnostic accuracy, though specificity remains limited. FES management is primarily supportive, focusing on maintaining oxygenation and hemodynamic stability, with invasive ventilation or extracorporeal support required in severe cases. Early fracture stabilization within 24 hours remains the most effective preventive strategy, whereas the use of corticosteroids is controversial owing to inconsistent efficacy and potential adverse effects. In this review, we aim to summarize current understanding of the diagnosis, management, and prevention of FES, while identifying unresolved clinical and research challenges. Relevant literature was identified through PubMed and Scopus searches of English language articles on traumatic and non-traumatic FES published up to 2025. Despite extensive clinical observation, many uncertainties persist regarding the pathophysiology, risk stratification, and optimal treatment of FES. Future directions include refinement of diagnostic criteria through integration of imaging, biomarkers, and artificial intelligence, as well as multicenter studies to establish evidence-based management strategies. Introduction: ‘grasping clouds’ as a metaphor The description of fat embolism syndrome (FES) is challenging owing to its complex and poorly understood nature. Although clouds exist in the sky, they are difficult to grasp. From the classical triad of FES, it has been described as respiratory distress, neurological dysfunction, and petechial rash by Gurd.1 Although it seems easy to grasp clinical manifestations, the symptoms or findings in radiological or laboratory examinations are not always the same; sometimes they are difficult to diagnose in real scenarios. The main feature of FES, as indicated by its name, is ‘embolism’; they are caused by the embolization of fat particles into multiple organs through arteries or veins, primarily affecting the lungs or the brain.2 Furthermore, cytokine reactions have also been reported to cause endothelial and parenchymal damage.3 In short, FES represents a complex interplay between vascular embolism and systemic inflammation, contributing to its heterogeneous clinical presentation. In this review, we aim to clarify the clinical features of FES and highlight key issues in its diagnosis and treatment strategies. Historical perspective and epidemiology This section outlines the historical evolution of the concept of FES and summarizes its reported incidence in clinical and autopsy studies. FES was first reported in 1861 when Zenker observed fat embolism in the capillaries of a patient who died from trauma complications.25 However, the true incidence and clinical significance of FES remain uncertain.6 In 1865, Wagner reported 48 FES cases, most involving fractures.7 As indicated previously, FES has been described in autopsy case reports in the early stages. Von Bergmann made the first clinical diagnosis of fat embolism based on his knowledge of its pathology,6 and the patient had a femoral fracture with dyspnea, cyanosis, and coma 60 hours after injury. Subsequent discussion of FES clinical aspects identified findings strongly suggestive of fat embolism.6 8 9 These are tachypnea, dyspnea, profuse tracheobronchial secretion, anxiety, apprehension, delirium, increasing unconsciousness, and petechial hemorrhages.6 10 Although many diagnostic criteria build on these early findings described previously,1 11 all remain limited by small sample sizes and lack of validation.3 The classical clinical triad includes respiratory distress, neurological dysfunction, and petechial rash, based on these discussions. Based on the clinical course of FES, treatment strategies for fractures, especially long bones, such as the femur, have been discussed. Riska et al first described the fixation timing of long bone fractures.12 Reports have concluded that early nailing of long bone fractures in patients with multiple trauma is associated with mortality or the incidence of FES.5 13 Another report showed long bone fractures and open fractures, or delay time to the operations, were associated with FES.14 However, delayed fixation leads to thromboembolic disease and prolonged hospital or intensive care unit (ICU) stay,15 and the effectiveness of nailing fixations12 in the early phase of injury16 has been demonstrated. The recommended treatment strategy for long bone fractures, particularly femoral fractures, has evolved over time. In the late 1980s, a prospective study on early fracture fixation reported early mobilization and a decrease in acute respiratory distress syndrome (ARDS) incidence.17 18 Although early definitive internal fixation for long bone fractures, called ‘early total care’,19 is advantageous for most, for some patients with severe trauma, a damage control orthopedics strategy, including external fixation followed by definitive treatment later, may increase the chance of survival.20 21 Based on these discussions, as Pape et al recommended, using the findings of shock, lung function, coagulopathy, temperature, fluid requirement, and soft tissue injury is crucial in deciding early surgical treatment13 22 for FES and for overall outcome. Following discussions on the timing of surgeries for internal fixation, the concepts of early appropriate care23 and safe definitive surgery13 have advanced after the 2010s. Traumatic and non-traumatic risk factors for FES have been proposed.3 24 Initial studies reported fat droplets or globules after trauma or femoral fracture in blood, lungs, or urine,10 25 26 and their incidence has varied (41–95%).5 A review article from 1995 reported that the incidence of traumatic fat embolism at autopsy was also high (40–100%).27 After the diagnostic criteria were used10 and internal fixation was instituted as a standard treatment, the incidence fell to the current rates, between 1.4% and 12.5%, after long bone fractures or trauma.2 5 FES incidence varied according to the background of the study. Stein et al analyzed the data from the National Hospital Discharge Survey and concluded that 0.004% of patients with FES were identified from the 928 324 patients from 1979 to 2005 in the USA.28 They also indicated that FES was more frequent in men and in patients aged 10–19 and 20–39 years. Multiple fractures of the femur (excluding the neck) are more often associated with FES compared with isolated fractures (1.29% vs. 0.54%). Fabian et al described that when hypoxemia was associated with a long bone or pelvic fracture, the incidence rate of FES was 11%.29 Chan et al reported an 8.75% FES rate in consecutive trauma cases and a rate of 35% in patients with multiple injuries.30 The estimated incidence of cerebral fat embolism (CFE) had not been identified.2 CFE incidence was 0.04% in patients with trauma admitted to the hospital,31 which was reported by Armstrong et al. Another report indicated 54 patients with CFE and FES in 38 case reports.32 They reported a 44.4% incidence rate for CFE after fracture injuries in the reviewed reports with MRI. As described above, FES incidence significantly differs between autopsy cases and clinical settings. Based on the autopsy findings, it seems that some ‘mistakes’ in the diagnosis in clinical scenarios may have happened. Kanda et al described the probability of CFE based on MRI findings in consecutive patients injured by high-energy trauma, including pelvic or femoral fractures,33 in their prospective study. It was concluded that 5% of patients were diagnosed with CFE based on magnetic resonance images. The results indicated that some cases of ‘fat embolism’, which had not clearly manifested as a ‘syndrome’, could exist. Understanding this historical and epidemiological background helps clinicians recognize why FES remains underdiagnosed and emphasizes the need for renewed and more objective diagnostic frameworks. Pathophysiology: beyond mechanical and biochemical theories Two theories have been suggested for the mechanism of FES: the ‘mechanical theory’ and the ‘biochemical theory’.727 3436 The mechanical theory was first described by Gauss,2 5 7 who postulated that external mechanical forces induce an increase in intramedullary pressure by traumatic injury or invasive surgery, and fat droplets are flooded into the venous system. The presence of bone marrow emboli in the lung or other organs, as described above, supports this.7 10 25 26 These fat emboli first lodge in the pulmonary microvasculature and then in the arterial circulation through right-to-left shunts, such as the patent foramen ovale and arteriovenous shunts,35 which can cause multiorgan failure. The biochemical theory has been presented as a biomechanical component in the pathophysiology of this syndrome. Fat globules entering the pulmonary vasculature lead to a microvascular inflammatory response, resulting in lung injury.7 37 In the brain, they cause local ischemia and inflammation through the inflammatory mediators, leading to neurological disorders. This theory has been confirmed by several reports; patients with FES have elevated levels of plasma phospholipase A2, proinflammatory cytokines, and free radicals.38 39 These findings may explain the delay of hours or days from the traumatic insult until the onset of clinical findings.37 Based on this theory, FES development after fat embolism may depend on the strength of the inflammatory response provoked.3 As indicated by the discussions of the two theories, FES should be reconsidered as a syndrome driven by microvascular endothelial injury, in which embolic and inflammatory processes converge to disrupt vascular homeostasis. We should redefine the basic concept of FES. We propose a conceptual shift from traditional symptom-based criteria toward a pathophysiology-oriented diagnostic framework. Specifically, this framework integrates the following domains: (1) risk factors (eg, long bone fractures, trauma severity), (2) clinical/imaging findings (eg, hypoxemia, MRI starfield pattern), and (3) biomarkers (eg, interleukin 6 (IL-6)). A composite scoring approach combining these domains may improve diagnostic accuracy compared with existing criteria. This integrated approach reflects the dual nature of FES as an embolic and an inflammatory disease and may enable early detection and risk stratification. Clinical spectrum and diagnostic challenges The clinical triad of symptoms described above does not typically occur simultaneously. For example, in respiratory distress, these symptoms occur first but not always, and a petechial rash is present in less than half of the cases. They can be mistaken for other diseases because their signs or symptoms are often non-specific. Patients with severe trauma are often intubated, and some sedatives may be administered to manage head or lung injuries. These situations can delay diagnosis. The need for a high index of suspicion in diagnosing FES is based on the patients’ background.2 40 Common diagnostic approaches for FES were proposed by Gurd and Wilson10 or by Lindeque.11 According to the Gurd and Wilson criteria, the main signs of FES are physiological or physical. However, they have been criticized for excluding arterial blood gas results, and Lindeque proposed criteria that included arterial blood gas findings.35 These parameters, which focus on the physiological and laboratory tests, are often observed in the context of other severe diseases such as sepsis in the ICU. Therefore, they might not capture the specific findings of FES. However, these diagnostic tools have not been validated in prospective studies, limiting the practical application of these criteria.3 20 No single diagnostic criterion has yet demonstrated sufficient accuracy for reliable diagnosis. Table 1 summarizes the commonly used diagnostic criteria and their limitations. In summary, although several diagnostic criteria have been proposed, none have been prospectively validated, and their sensitivity and specificity remain limited. This highlights the need for new approaches that combine imaging and biomarkers (table 1). Table 1Diagnostic criteria for FESCriteriaMajor featuresMinor featuresStrengthsLimitationsGurd and Wilson10≥1 major (petechiae, hypoxemia, CNS depression, pulmonary edema)≥4 minor (tachycardia, fever, anemia, thrombocytopenia, retinal changes, fat macroglobulinemia)Historically widely citedNo validation, subjective findings, and insensitiveLindeque11Based on PaO₂ <60 mm Hg, PaCO₂ >55 mm Hg, RR >35/min, GCS score <14NoneObjective, physiologicalFocuses only on respiratory/neurological symptoms, ignores rash/petechiaeSchonfeld Score59Cumulative scoring: petechiae (5), diffuse chest infiltrates (4), hypoxemia (3), fever (1), tachycardia (1), tachypnea (1), confusion (1)Cut-off ≥5=FESSemiquantitativeNot prospectively validated, low specificityCNS, central nervous system; FES, fat embolism syndrome; GCS, Glasgow Coma Scale; PaCO₂, partial pressure of carbon dioxide; PaO₂, partial pressure of oxygen; RR, respiration rate. Diagnostic criteria for FES CNS, central nervous system; FES, fat embolism syndrome; GCS, Glasgow Coma Scale; PaCO₂, partial pressure of carbon dioxide; PaO₂, partial pressure of oxygen; RR, respiration rate. Advances in imaging and biomarkers Based on the background of the criteria, which consisted of non-specific clinical features and laboratory tests,35 41 an imaging examination would be a useful tool for the diagnosis of these syndromes. Specific imaging findings of FES have been described previously.20 35 For example, chest radiograph abnormalities are found in approximately 30–50% of FES cases.41 42 They may present as bilateral diffuse, patchy infiltrates, or as consolidations from pulmonary edema and alveolar hemorrhage.43 Although these findings could be beneficial for evaluating FES, they lack diagnostic value because they are non-specific to FES.35 43 Chest CT has also been described as a useful tool for diagnosing FES.44 CT abnormalities include patchy, well-demarcated ground-glass opacities44 and septal thickening.45 Additionally, differential diagnoses, including pulmonary embolism, bacterial pneumonia, sepsis, ARDS, and COVID, should be considered because of their non-specific nature.3 Brain CT or MRI is helpful in diagnosing CFE. Kuo et al proposed that brain MRI using T2-weighted with diffusion-weighted imaging, gadolinium contrast-enhanced images, and susceptibility-weighted imaging has improved diagnostic ability.4 They also described interesting findings from brain MRI: five distinctive patterns of CFE, which depended on the onset time. The ‘starfield pattern’, which is the most well-known finding of CFE, is a non-specific feature observed in many embolic events and is often reversible.4 Previous studies report that the ‘starfield pattern’ is observed in 61.5–84.6% of cases of CFE, whereas its frequency is markedly lower in the subacute and late stages.4 46 Kanda et al indicated the possibility of FES in patients with slight mental disturbances, delirium, or altered alertness, even without the completion of diagnostic criteria.33 There have also been reports about biomarkers of FES. IL-6 has been described as the key marker of FES.39 47 As indicated in the literature, IL-6 could be elevated by other factors among treatment strategies or combined injuries of FES; the role of IL-6 in diagnostic criteria has not been understood. Although Kuwata described the relationship between fat embolism and endothelial glycocalyx in rats,48 little is known about this relationship in humans. Given the heterogeneity and non-specific presentation of FES, artificial intelligence may be particularly useful for integrating multimodal data, including imaging, clinical parameters, and biomarkers, thereby supporting earlier and more accurate diagnosis.4951 Management strategies Although occasionally described as ‘self-limiting’,36 the syndrome may present with right ventricular dysfunction, biventricular failure, ARDS, shock, and death.37 FES presents 1–3 days after injury.28 34 FES has often been discussed within the treatment strategies of severe trauma, including fractures, especially long bone fractures.2 13 18 Treatment is primarily supportive care with the goal of maintaining oxygenation and hemodynamic stability, reflecting the lack of disease-specific therapies targeting the underlying pathophysiology.20 Patients with suspected FES should be admitted to the ICU, where they can benefit from physiological monitoring, including early invasive treatments.3 In cases of respiratory failure, invasive ventilatory support is required in up to 44% of FES cases; however, no specific ventilatory strategies have been developed.3 16 Sometimes, prone positioning or extracorporeal membrane oxygenation (ECMO) may be necessary.52 No specific management strategy exists for CFE. General principles for managing patients with brain injury include monitoring intracranial pressure or follow-up brain CT imaging to prevent a secondary brain injury.3 Although neurological complications are usually managed conservatively,3 some cases require craniotomy to manage intracranial pressure and improve outcomes.53 Specific drug treatments have not been established.3 Additionally, no accepted treatment algorithms for multiple trauma or fractured patients with FES have been reported. Prevention and orthopedic considerations Table 2 provides a comparative overview of the current strategies for treating and preventing FES, highlighting the established evidence and unresolved issues. In summary, early fracture stabilization remains the most reliable preventive strategy, whereas pharmacologic interventions, such as corticosteroid administration, have shown inconsistent results. Supportive intensive care remains the cornerstone of management (table 2). Table 2Treatment and preventive strategies in FESStrategyEvidence/findingsLimitationsEarly fracture fixationEarly nailing reduces ARDS incidence, improves mobilization.Not feasible in unstable polytrauma; risk of ‘second hit’.DCOExternal fixation, then delayed internal fixation, improves survival in unstable trauma.Requires staged operations, longer hospital stay.CorticosteroidsMeta-analyses suggest reduced FES incidence and hypoxemia.No mortality benefit; infection risk; not standard of care.Supportive care (ICU, ventilation)Mainstay of management; invasive ventilation is required in up to 44%.No disease-specific protocol.ECMO (VV-ECMO)Case reports show rescue in severe ARDS.Very limited data, high resource use.Other pharmacologic interventions (antiplatelet drugs, statins, RAAS modulators)Preclinical or anecdotal.No clinical trial evidence.ARDS, acute respiratory distress syndrome; DCO, damage control orthopedics; ECMO, extracorporeal membrane oxygenation; FES, fat embolism syndrome; ICU, intensive care unit; RAAS, renin-angiotensin-aldosterone system; VV, venovenous. Treatment and preventive strategies in FES ARDS, acute respiratory distress syndrome; DCO, damage control orthopedics; ECMO, extracorporeal membrane oxygenation; FES, fat embolism syndrome; ICU, intensive care unit; RAAS, renin-angiotensin-aldosterone system; VV, venovenous. Controlling or eliminating risk factors earlier (within the first 24 hours) after injury is vital for CFE/FES prevention. These include early stabilizations of fractures with external or internal fixation, optimal treatment strategies for long bone fractures, and immobilization.36 54 Also, early fracture stabilization and reductions improve the mortality rate with multiple injuries.55 The timing of internal fixation for fractures in severe injuries has long been debated, with strategies such as early total/appropriate care23 or damage control orthopedics.13 56 57 Bederman et al suggested that corticosteroids may be beneficial in preventing FES and hypoxia but not mortality in patients with long bone fractures.58 Despite these effects, the authors have cautioned against the negative effects of corticosteroids, including secondary infections.3 58 Future directions: from fog to clarity This section outlines the key knowledge gaps and future research priorities in FES. Many aspects of FES remain unclear, including its epidemiology, diagnostic criteria, and treatments. FES can cause symptoms associated with vascular embolism throughout the body and may cause systemic inflammation. The imaging patterns change with time. Although many fractures have been identified as risk factors for FES in previous reports, some patients develop symptoms that can be fatal, whereas others may remain asymptomatic. Although the management of FES is primarily supportive, it remains unclear which patients are at risk of progression to severe disease and may require advanced interventions such as ECMO. Therefore, risk stratification remains an important unmet need (figure 1). An outlined figure that describes the mechanism of fat embolism syndrome or organ dysfunctions. AV, arteriovenous; PFO, patent foramen ovale. As indicated above, the diagnostic criteria for FES have not been prospectively validated; they should be updated based on the latest findings. Most existing studies are limited by used small sample sizes, highlighting the need for large-scale investigations using international registries or multicenter trials. The integration of image findings and biomarkers may play a key role in risk stratification. These advances may help clear the "fog" that has long obscured the understanding of this condition. For example, a future diagnostic model could integrate clinical risk factors, imaging findings such as CT or MRI patterns, and biomarkers including IL-6 into a composite scoring system to enable earlier diagnosis and more accurate risk stratification. Conclusion FES has many aspects of clinical manifestations; therefore, it has been difficult to understand, like "grasping the clouds.” But recent studies have made the disease more "visible." Future studies in this field could clarify the unsolved issues.